Literature DB >> 3459569

Peripheral erythroid precursor and prognosis in chronic granulocytic leukemia.

A Levis, F Marmont, M A Ciocca Vasino, A Jayme, V Infelise, G Cametti, M Canta, L Resegotti.   

Abstract

Seventy-four consecutive patients with nonblastic chronic granulocytic leukemia (CGL) were observed from diagnosis and retrospectively studied. The patients were segregated into three risk groups according to the staging system proposed by Sokal et al. A significant difference in survival was observed only between Stage I and III (P = 0.01). The prognostic role of other variables, different from those considered in the Sokal et al. equation, was then investigated. Multiple regression analysis of data was made, by forcing into the Cox's regression model the Sokal et al. equation, while allowing the remaining variables to move in and out of the model. Only the presence of peripheral nucleated erythrocytes improved the significance (chi-square improvement = 4.565; P value improvement = 0.033). The evaluation of peripheral erythroid precursors is proposed for further implementation of the staging systems in CGL.

Entities:  

Mesh:

Year:  1986        PMID: 3459569     DOI: 10.1002/1097-0142(19860715)58:2<229::aid-cncr2820580205>3.0.co;2-3

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  Histological features of prognostic significance in CML--an immunohistochemical and morphometric study (multivariate regression analysis) on trephine biopsies of the bone marrow.

Authors:  J Thiele; H M Kvasnicka; B R Titius; U Parpert; R Nebel; R Zankovich; D Dienemann; H Stein; V Diehl; R Fischer
Journal:  Ann Hematol       Date:  1993-06       Impact factor: 3.673

2.  Confirmation and improvement of Sokal's prognostic classification of Ph+ chronic myeloid leukemia: the value of early evaluation of the course of the disease. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.

Authors: 
Journal:  Ann Hematol       Date:  1991-12       Impact factor: 3.673

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.